Burek, Alina G.
Bumgardner, Chris
Liljestrom, Tracey
Porada, Kelsey
Pan, Amy Y.
Liegl, Melodee
Coon, Eric R.
Flynn, Kathryn E.
Ullman, Amanda J.
Brousseau, David C.
Article History
Received: 4 January 2024
Revised: 23 May 2024
Accepted: 4 June 2024
First Online: 27 June 2024
Competing interests
: Kathryn Flynn has received consultancy funding from Inhibikase, Pfizer, and Novartis unrelated to this work. Amanda Ullman’s employer (UQ) has received investigator-initiated research grants from vascular access product manufacturers (3 M, Becton Dickinson, Medline) on behalf of her research, unrelated to the submitted project. David Brousseau receives consultancy funding from CSL Behring unrelated to this work. The remaining authors have no conflicts of interest to disclose.